Home›Clinical trials›Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostat

A study of a GLP-1 and GIP medicine, tirzepatide, in people with prostate cancer.

Recruiting now. Registry record last updated August 17, 2026.

Who can join
Adults 30 to 79, have prostate cancer, BMI 27+.
What you take
Tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts
The full study runs about 2 years.
What you get
Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.
This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.
Check my fit →
Phase Phase 2Sponsor City of Hope Medical CenterDrug tirzepatideClass GLP-1/GIPSites 1 USEnrollment target 60

What this study is for

Primary condition: Prostate Carcinoma. Also studied in: Recurrent Prostate Carcinoma.

Full scientific study title: Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostat.

Who can join

Age30 to 79SexMaleBMI27 or higher

Adults 30 to 79, have prostate cancer, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Documented informed consent of the participant
  • English, Spanish or Mandarin-speaking
  • Agreement to allow the use of archival tissue from diagnostic tumor biopsies
  • If unavailable, exceptions may be granted with study principal investigator (PI) approval
  • Male

Key exclusion criteria

  • Currently engaging in strict macronutrient/time limited diet, including ketogenic, low-carb, paleo, or warrior diet
  • Currently under GLP1-RA therapy
  • Poorly controlled diabetes
  • Unable to undergo time-restricted diet
  • Contraindications for GLP1-RA therapy: including hypersensitivity to the drug, personal history of pancreatitis, personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2, end-stage renal disease

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

California1 site

Timeline

Started enrolling: November 5, 2025. Expected completion: April 9, 2028. Last updated on ClinicalTrials.gov: August 17, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.